Mavorixafor is a small molecule commercialized by X4 Pharmaceuticals, with a leading Pre-Registration program in WHIM Syndrome (Warts, Hypogammaglobulinemia, Infections and Myelokathexis). According to Globaldata, it is involved in 13 clinical trials, of which 6 were completed, 3 are ongoing, 2 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Mavorixafor’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Mavorixafor is expected to reach an annual total of $80 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Mavorixafor Overview

Mavorixafor (X4P-001) is under development for the treatment of severe congenital neutropenia, Waldenstrom’s Macroglobulinemia, WHIM syndrome, melanoma and refractory solid tumors including clear cell renal cell carcinoma (ccRCC) and triple-negative breast cancer. It is administered through oral route. The drug candidate was under development for the treatment of human immunodeficiency virus (HIV) Infections (AIDS). The drug candidate acts by targeting C-X-C receptor type 4 (CXCR4).

X4 Pharmaceuticals Overview

X4 Pharmaceuticals, formerly Arsanis, is a clinical-stage biopharmaceutical company, that develops oral, small molecule therapeutics to treat cancer and rare diseases. The company’s pipeline products include Mavorixafor, an allosteric inhibitor of CXCR4 for the treatment of warts, hypogammaglobulinemia, immunodeficiency and myelokathexis (WHIM) syndrome X4P-002 and X4P-003, small molecule antagonists of chemokine receptor CXCR4 for treating glioblastoma multiforme and primary immune deficiencies (PI’s). The company is developing oral allosteric antagonists of CXCR4 in order to block overstimulation of the CXCL12/CXCR4 pathway that enables the trafficking of immune cells and effective immunosurveillance. X4 is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$87.6 million in FY2022, compared to an operating loss of US$85.1 million in FY2021. The net loss of the company was US$93.9 million in FY2022, compared to a net loss of US$88.7 million in FY2021.

For a complete picture of Mavorixafor’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.